<SEC-DOCUMENT>0001104659-19-031256.txt : 20190523
<SEC-HEADER>0001104659-19-031256.hdr.sgml : 20190523
<ACCEPTANCE-DATETIME>20190523061714
ACCESSION NUMBER:		0001104659-19-031256
CONFORMED SUBMISSION TYPE:	3/A
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20190522
FILED AS OF DATE:		20190523
DATE AS OF CHANGE:		20190523

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Hau Bosun
		CENTRAL INDEX KEY:			0001730224

	FILING VALUES:
		FORM TYPE:		3/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38916
		FILM NUMBER:		19847912

	MAIL ADDRESS:	
		STREET 1:		17901 VON KARMAN AVENUE, SUITE 150
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BICYCLE THERAPEUTICS Ltd
		CENTRAL INDEX KEY:			0001761612
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	BUSINESS ADDRESS:	
		STREET 1:		B900 BABRAHAM RESEARCH CAMPUS
		CITY:			CAMBRIDGE
		STATE:			X0
		ZIP:			CB22 3AT
		BUSINESS PHONE:		011441223261503

	MAIL ADDRESS:	
		STREET 1:		B900 BABRAHAM RESEARCH CAMPUS
		CITY:			CAMBRIDGE
		STATE:			X0
		ZIP:			CB22 3AT
</SEC-HEADER>
<DOCUMENT>
<TYPE>3/A
<SEQUENCE>1
<FILENAME>a3a.xml
<DESCRIPTION>3/A
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3/A</documentType>

    <periodOfReport>2019-05-22</periodOfReport>

    <dateOfOriginalSubmission>2019-05-22</dateOfOriginalSubmission>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001761612</issuerCik>
        <issuerName>BICYCLE THERAPEUTICS Ltd</issuerName>
        <issuerTradingSymbol>BCYC</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001730224</rptOwnerCik>
            <rptOwnerName>Hau Bosun</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O BICYCLE THERAPEUTICS PLC</rptOwnerStreet1>
            <rptOwnerStreet2>B900, BABRAHAM RESEARCH CAMPUS</rptOwnerStreet2>
            <rptOwnerCity>CAMBRIDGE</rptOwnerCity>
            <rptOwnerState>X0</rptOwnerState>
            <rptOwnerZipCode>CB 22 3AT</rptOwnerZipCode>
            <rptOwnerStateDescription>UNITED KINGDOM</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Series B2 Preferred Shares</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F1"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Ordinary Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>1454411</value>
                    <footnoteId id="F2"/>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By Aquila Investments IV</value>
                    <footnoteId id="F3"/>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Series B1 Preferred Shares Warrants</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F4"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F4"/>
            </exerciseDate>
            <expirationDate>
                <value>2025-03-31</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Series B1 Preferred Shares</value>
                    <footnoteId id="F1"/>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>139264</value>
                    <footnoteId id="F2"/>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By Aquila Investments IV</value>
                    <footnoteId id="F3"/>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Each Series B1 Preferred Share and Series B2 Preferred Share shall automatically convert into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.</footnote>
        <footnote id="F2">Share numbers give effect to the bonus shares issued to each holder of ordinary shares on the basis of 1.429 bonus shares for each ordinary share in issue, effective on May 13, 2019, which will be effective for the ordinary shares upon their conversion to ordinary shares upon the closing of the Issuer's initial public offering. The number of shares reflects the conversion of the Series B1 Preferred Shares and Series B2 Preferred Shares to Ordinary Shares set out in footnote (1).</footnote>
        <footnote id="F3">The shares are held by Aquila Investments IV, an affiliate of Tybourne Capital Management.  The Reporting Person is the Managing Director and Co-Head of Private Equity at Tybourne Capital Management .</footnote>
        <footnote id="F4">The Warrants to Purchase Series B1 Preferred Shares have an exercise price of a nominal value per share. The Warrants are immediately exercisable and expire on March 31, 2025.</footnote>
    </footnotes>

    <remarks>This Form 3/A amends the Reporting Person's Form 3 filed on May 22, 2019 to correct typographical errors in Table II,  Column 3 (Title and Amount of Securities Underlying Derivative Security (Instr. 4)).</remarks>

    <ownerSignature>
        <signatureName>/s/ Lee Kalowski, as Attorney-in-Fact</signatureName>
        <signatureDate>2019-05-23</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
